X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
ADCOCK INGRAM
Jun-14
GLENMARK PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs993403-   
Low Rs729291-   
Sales per share (Unadj.) Rs325.5119.9-  
Earnings per share (Unadj.) Rs39.3-30.2-  
Cash flow per share (Unadj.) Rs48.7-25.0-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs159.294.1-  
Shares outstanding (eoy) m282.17168.78-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.62.9 91.4%   
Avg P/E ratio x21.9-11.5 -190.9%  
P/CF ratio (eoy) x17.7-13.9 -127.7%  
Price / Book Value ratio x5.43.7 146.7%  
Dividend payout %5.10-   
Avg Mkt Cap Rs m242,99158,557 415.0%   
No. of employees `00013.04.3 302.0%   
Total wages/salary Rs m16,4083,675 446.5%   
Avg. sales/employee Rs Th7,083.94,714.3 150.3%   
Avg. wages/employee Rs Th1,265.4856.1 147.8%   
Avg. net profit/employee Rs Th855.1-1,187.9 -72.0%   
INCOME DATA
Net Sales Rs m91,85720,238 453.9%  
Other income Rs m374142 263.6%   
Total revenues Rs m92,23020,380 452.6%   
Gross profit Rs m20,367-3,507 -580.7%  
Depreciation Rs m2,644873 302.7%   
Interest Rs m2,373548 432.9%   
Profit before tax Rs m15,724-4,787 -328.5%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,827299 1,279.3%   
Profit after tax Rs m11,088-5,100 -217.4%  
Gross profit margin %22.2-17.3 -127.9%  
Effective tax rate %24.3-6.2 -389.5%   
Net profit margin %12.1-25.2 -47.9%  
BALANCE SHEET DATA
Current assets Rs m68,74614,823 463.8%   
Current liabilities Rs m27,0278,340 324.1%   
Net working cap to sales %45.432.0 141.8%  
Current ratio x2.51.8 143.1%  
Inventory Days Days85111 76.6%  
Debtors Days Days96124 77.1%  
Net fixed assets Rs m24,1328,640 279.3%   
Share capital Rs m28294 300.3%   
"Free" reserves Rs m44,6430-   
Net worth Rs m44,92515,885 282.8%   
Long term debt Rs m45,3635,582 812.6%   
Total assets Rs m117,63930,008 392.0%  
Interest coverage x7.6-7.7 -98.6%   
Debt to equity ratio x1.00.4 287.3%  
Sales to assets ratio x0.80.7 115.8%   
Return on assets %11.4-15.2 -75.4%  
Return on equity %24.7-32.1 -76.9%  
Return on capital %19.1-19.8 -96.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m48,0680-   
CASH FLOW
From Operations Rs m6,5741,727 380.6%  
From Investments Rs m-7,124-530 1,343.0%  
From Financial Activity Rs m5,4325,066 107.2%  
Net Cashflow Rs m1,9926,263 31.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.56 Rs / ZAR

Compare GLENMARK PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: PANACEA BIOTECH  J.B.CHEMICALS  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  SHASUN PHARMA  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views On News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS